Standard AAV serotypes provide a foundational toolkit for gene therapy, but targeting novel biological pathways with precision requires a more tailored vector. Custom AAV vector design moves beyond off-the-shelf solutions to engineer vectors with enhanced tissue specificity, optimized transgene expression, and refined immunogenic profiles. This strategy is built on a deep understanding of vector biology and its interaction with host systems, directly impacting the translational potential and clinical risk profile of a therapeutic candidate. For programs targeting global markets, including submissions to Swissmedic, EMA, and the FDA, this level of vector optimization provides a robust data package supporting efficacy and safety.

Engineering AAV Vectors for Novel Therapeutic Hypotheses

The utility of AAV as a delivery vehicle is well-established. Yet, unlocking its full potential for complex indications requires moving beyond canonical serotypes. A tailored preclinical strategy begins with the vector itself, engineering constructs to meet the specific biological challenges of a target pathway. This involves a data-driven process of capsid selection, promoter optimization, and transgene modification to achieve the desired expression profile while minimizing liabilities.

This approach is informed by decades of experience. The scientific leadership and core team at Franklin Biolabs, formally launched in 2024, maintain a 100% successful IND rate since 2019, a track record built on this foundational principle of bespoke vector design.

Enhancing Efficacy Through Molecular Design

A primary goal of vector engineering is to maximize therapeutic protein expression in the target tissue. This can involve designing gain-of-function variants of a transgene that possess superior biological activity. For instance, engineering a therapeutic payload to be resistant to natural degradation pathways can significantly amplify its efficacy without increasing the vector dose (PMID: 25023731). This level of molecular refinement is a key differentiator for programs entering competitive therapeutic areas.

Key considerations for efficacy-driven vector design include:

• Promoter/Enhancer Selection: Choosing regulatory elements that drive robust and tissue-specific expression.

• Codon Optimization: Adapting the transgene sequence for optimal translation in human cells.

• Transgene Engineering: Modifying the therapeutic protein itself for enhanced stability or activity.

This integrated approach combines deep expertise in vector production and analytics with a collaborative framework, ensuring that vector development aligns precisely with the partner’s therapeutic program objectives.